GlassScriptPhysician profile
Joanna B Thomas
NPI 1275768855
$2,445.28
in general payments reported to CMS, 2019-2025
25 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.89 · 2020: $11.88 · 2021: $56.60 · 2022: $127 · 2023: $368 · 2024: $1,258 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Entertainment: $14.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.45 |
| Entertainment | $14.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $595.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $287.46 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $247.26 | 2023-2025 | |
| Abbott Laboratories | $244.46 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.40 | 2019-2025 | Jardiance |
| Amgen INC. | $158.66 | 2023-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $136.06 | 2021-2025 | Trintellix |
| Abbvie INC. | $116.46 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.34 | 2023-2024 | Shingrix, Arexvy |
| Dexcom, INC. | $59.66 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.08 | 2023-2024 | Xifaxan |
| Astellas Pharma US INC | $33.02 | 2024-2025 | Veozah |
| Esperion Therapeutics, INC. | $31.55 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $29.79 | 2023-2024 | Xarelto |
| Genentech USA, INC. | $25.93 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.14 | 2024 | Gvoke Hypopen |
| Blueprint Medicines Corporation | $20.64 | 2024 | Ayvakit |
| Corium, LLC | $18.47 | 2023 | Adlarity |
| Philips North America LLC | $18.08 | 2024 | (Ck6) Holter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.95 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $15.38 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.71 | 2025 | Voquezna |
| Optos, INC. | $14.35 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.16 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.